Company intelligence / Profile preview
Nippon Chemiphar
Chiyoda-ku/Iwamotochou, Tokyo, Japanchemiphar.co.jp ↗
- Ownership
- Private
- Employees
- ~855
- Development stage
- Other
01
Overview
Nippon Chemiphar has a diverse pipeline with several small molecule drug candidates in early clinical development targeting metabolic diseases, pain, CNS disorders, and oncology. The company also markets generic drugs and diagnostic agents. Notable clinical-stage assets include NC‑2400 (PPAR-delta agonist), NC‑2500 (XOR inhibitor), NC‑2600 (P2X4 antagonist), DFP‑17729 for pancreatic cancer microenvironment improvement, DE-P‑14323 for non-small cell lung cancer, Calvan for Huntington’s disease—all at various stages from preclinical to phase 2 trials. The company is also active in the generic drug market and diagnostics.
- Therapeutic areas
- PsychiatryRheumatologyOncologyNeurology
- Modalities
- Small moleculeDiagnostic deviceBiologic
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Nippon Chemiphar.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nippon Chemiphar.